Reply

Hepatology

Volumn 61, Issue 6, 2015, Pages 2119-2120

  Martinez, Melissa ^a   Tandra, Anand ^b   Vuppalanchi, Raj ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDEXANET ALFA; ANTIDOTE; APIXABAN; PROTHROMBIN COMPLEX; RIVAROXABAN; ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; LETTER; LIVER CIRRHOSIS; PRIORITY JOURNAL; THROMBOSIS; TOXIC HEPATITIS; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING; MALE; MESENTERIC VEIN; PORTAL VEIN; VENOUS THROMBOSIS;

ANTICOAGULANTS; HUMANS; MALE; MESENTERIC VEINS; MORPHOLINES; PORTAL VEIN; THIOPHENES; VENOUS THROMBOSIS;

EID: 84929606549     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27542     Document Type: Letter

References (3)

1. Potze W, Arshad F, Adelmeijer J, Blokzjil H, van den Berg AP, Meijers JC, et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 2014;9:e88390.
2. Potze W, Adelmeijer J, Lisman T. Decreased in vitro potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology 2014 Aug 1. doi: 10.1002/hep.27350. [Epub ahead of print]
3. Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury. J Hepatol 2014;61:293-300.